摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(4-chloronaphthalen-1-yl)oxy]benzaldehyde

中文名称
——
中文别名
——
英文名称
4-[(4-chloronaphthalen-1-yl)oxy]benzaldehyde
英文别名
4-(4-Chloronaphthalen-1-yl)oxybenzaldehyde
4-[(4-chloronaphthalen-1-yl)oxy]benzaldehyde化学式
CAS
——
化学式
C17H11ClO2
mdl
——
分子量
282.726
InChiKey
ZSVXMEFZMDNDOI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-[(4-chloronaphthalen-1-yl)oxy]benzaldehydesilver(l) oxidelithium hexamethyldisilazane 作用下, 以 四氢呋喃正己烷甲苯 为溶剂, 反应 4.83h, 生成 ethyl 3-{4-[(4-chloronaphthalene-1-yl)oxy]phenyl}-3-ethoxypropanoate
    参考文献:
    名称:
    Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558
    摘要:
    GPR40 agonists stimulate insulin secretion only under the presence of high glucose concentration. Based on this mechanism, GPR40 agonists are believed to be promising novel insulin secretagogues with low risk of hypoglycemia. The optimizations of 3-aryl-3-ethoxypropanoic acids were performed to improve in vitro activity. We discovered compound 29r (DS-1558), (3S)-3-ethoxy-3-(4-{[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy}phenyl)propanoic acid, which was confirmed to have an enhancing effect on glucose-dependent insulin secretion after intravenous glucose injection in SD rats. (C) 2015 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2015.07.028
  • 作为产物:
    描述:
    对氟苯甲醛4-氯-1-萘酚caesium carbonate 作用下, 以 N,N-二甲基乙酰胺 为溶剂, 反应 3.0h, 以33%的产率得到4-[(4-chloronaphthalen-1-yl)oxy]benzaldehyde
    参考文献:
    名称:
    Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558
    摘要:
    GPR40 agonists stimulate insulin secretion only under the presence of high glucose concentration. Based on this mechanism, GPR40 agonists are believed to be promising novel insulin secretagogues with low risk of hypoglycemia. The optimizations of 3-aryl-3-ethoxypropanoic acids were performed to improve in vitro activity. We discovered compound 29r (DS-1558), (3S)-3-ethoxy-3-(4-{[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy}phenyl)propanoic acid, which was confirmed to have an enhancing effect on glucose-dependent insulin secretion after intravenous glucose injection in SD rats. (C) 2015 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2015.07.028
点击查看最新优质反应信息

文献信息

  • Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558
    作者:Rieko Takano、Masao Yoshida、Masahiro Inoue、Takeshi Honda、Ryutaro Nakashima、Koji Matsumoto、Tatsuya Yano、Tsuneaki Ogata、Nobuaki Watanabe、Masakazu Hirouchi、Takako Kimura、Narihiro Toda
    DOI:10.1016/j.bmc.2015.07.028
    日期:2015.9
    GPR40 agonists stimulate insulin secretion only under the presence of high glucose concentration. Based on this mechanism, GPR40 agonists are believed to be promising novel insulin secretagogues with low risk of hypoglycemia. The optimizations of 3-aryl-3-ethoxypropanoic acids were performed to improve in vitro activity. We discovered compound 29r (DS-1558), (3S)-3-ethoxy-3-(4-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy}phenyl)propanoic acid, which was confirmed to have an enhancing effect on glucose-dependent insulin secretion after intravenous glucose injection in SD rats. (C) 2015 Elsevier Ltd. All rights reserved.
查看更多